^(177)Lu-DOTATATE 治疗神经内分泌肿瘤的研究进展  

Research progress of ^(177)Lu-DOTATATE in the treatment of neuroendocrine neoplasms

作　　者：董瑞雪 晋建华[1] Dong Ruixue;Jin Jianhua(Department of Nuclear Medicine,First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一医院核医学科,太原030001

出　　处：《国际放射医学核医学杂志》2024年第9期588-594,共7页International Journal of Radiation Medicine and Nuclear Medicine

摘　　要：多肽偶联药物是一种新兴的肿瘤靶向治疗药物,具有相对分子质量小、肿瘤细胞穿透性强及免疫原性低等特点,在肿瘤分子显像和靶向治疗中受到越来越高的重视。^(177)Lu-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-D-苯丙氨酸1-酪氨酸3-苏氨酸8-奥曲肽(DOTATATE)作为最成功的多肽偶联药物,可特异性地与生长抑素受体(SSTR)相结合,实现肿瘤的肽受体放射性核素治疗。笔者就近年来有关^(177)Lu-DOTATATE在神经内分泌肿瘤中的治疗疗效、剂量选择及改善策略等方面的研究进展进行综述,为SSTR过表达肿瘤的靶向治疗提供参考。Polypeptide drug conjugate are an emerging tumor-targeted therapy drug with the characteristics of small molecular weight,strong tumor cell penetration,and low immunogenicity,which has received increasing attention in molecular imaging and targeted therapy of tumors.^(177)Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-D-Phe1-Tyr3-Thr8-octreotide(DOTATATE),as the most successful polypeptide drug conjugate,can specifically bind to the somatostatin receptor(SSTR)to achieve peptide receptor radionuclide therapy for tumors.The author reviews the research progress on the therapeutic efficacy,dose selection,and improvement strategies of ^(177)Lu-DOTATATE in neuroendocrine neoplasms,to provide a reference for the targated therapy of SSTR overexpression tumors.

关 键 词：神经内分泌瘤 受体 肽 有机金属化合物 同位素标记 镥 正电子发射断层显像术 体层摄影术 X线计算机 

分 类 号：R739.4[医药卫生—肿瘤]